HMGCR and cancer: In addition, observational studies of cholesterol-lowering drug use (i.e. HMG-CoA reductase inhibitors, aka statins) and cancer incidence, which include large numbers of PCa patients and a substantial number with advanced disease, show an inverse association between statin use and PCa incidence and/or progression, including a significant reduction in risk of advanced disease with long term statin use [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24].